MTR, founded in 2018, is an early stage company developing a new class of radiopharmaceuticals for Dx and Tx of solid tumors utilizing the overexpression of PARP-1 in tumor tissue. PARP is located on the DNA itself making PARP an ideal target for radionuclide based precision medicine. The precisely targeting of tumors with a radiolabeled PARP inhibitor offers both an unique diagnostic & staging potential and highly efficient & precisely targeted tumor therapy with minimal side effects.
There continues to be a high unmet medical need for a potent anti-cancer therapy that includes efficacy against tumors that are currently poorly treatable or show multi-drug resistance. The MTR technology is deeply rooted in the theranostics principle in molecular medicine combining both diagnostic imaging and therapy with the same molecule being radiolabeled differently. This integrated companion approach deposits a highly targeted lethal payload to tumor tissue addressing even small therapy-resistant refractory lesions without systemic toxicity.
Result: A new generation of targeted cancer Dx & Tx in a novel approach.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Am Schloßberg 40, Waldburg,baden-Württemberg 88289,germany
- Phone
- +49 7529 913 2275
- in****@****rma.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- mt-radiopharma.com
- Keywords
- Brisbane.
- HQ
- Waldburg, Baden-Württemberg
- Competitors
- ESRR - European Symposium on Radiopharmacy and Radiopharmaceuticals, Isologic Innovative Radiopharmaceuticals (Isologic), Aviko Radiopharmaceuticals, LANTHEUS MI RADIOPHARMACEUTICALS, INC, ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals, Nucleis - Radiopharmaceuticals, Coquí RadioPharmaceuticals, Corp., Cerberus Radiopharmaceuticals, Meridian Radiopharmaceuticals.
Molecular Targeted Radiopharmaceuticals Holding Gmbh Questions
Molecular Targeted Radiopharmaceuticals Holding Gmbh's helpline number is +49 7529 913 2275
Molecular Targeted Radiopharmaceuticals Holding Gmbh's website is mt-radiopharma.com
Molecular Targeted Radiopharmaceuticals Holding Gmbh's LinkedIn profile is https://de.linkedin.com/company/mt-radiopharma
Molecular Targeted Radiopharmaceuticals Holding Gmbh has
2 employees.
View email and phone details for 2
employees at Molecular Targeted Radiopharmaceuticals Holding Gmbh.
Molecular Targeted Radiopharmaceuticals Holding Gmbh's industry is
Pharmaceutical Manufacturing
Molecular Targeted Radiopharmaceuticals Holding Gmbh's top competitors are
Esrr - European Symposium On Radiopharmacy And Radiopharmaceuticals,
Isologic Innovative Radiopharmaceuticals (Isologic),
Aviko Radiopharmaceuticals,
Lantheus Mi Radiopharmaceuticals, Inc,
Arc Research Hub For Advanced Manufacture Of Targeted Radiopharmaceuticals,
Nucleis - Radiopharmaceuticals,
Coquí Radiopharmaceuticals, Corp.,
Cerberus Radiopharmaceuticals,
Meridian Radiopharmaceuticals.
Molecular Targeted Radiopharmaceuticals Holding Gmbh's support email address is info@mt-radiopharma.com
Molecular Targeted Radiopharmaceuticals Holding Gmbh's categories are Pharmaceutical Manufacturing
Molecular Targeted Radiopharmaceuticals Holding Gmbh's founding year is 2018
